Detection and assessment of alpha-synuclein in Parkinson disease

被引:5
作者
Tsao, Hsien-Hao [1 ]
Huang, Chung-Guei [2 ,3 ,4 ]
Wu, Yih-Ru [5 ,6 ]
机构
[1] Chang Gung Mem Hosp, Linkou Med Ctr, Dept Neurol, Taoyuan, Taiwan
[2] Chang Gung Mem Hosp, Linkou Med Ctr, Dept Lab Med, Taoyuan, Taiwan
[3] Chang Gung Univ, Coll Med, Dept Med Biotechnol & Lab Sci, Taoyuan, Taiwan
[4] Chang Gung Univ, Coll Med, Res Ctr Emerging Viral Infect, Taoyuan, Taiwan
[5] Chang Gung Univ, Chang Gung Mem Hosp Linkou Med Ctr, Dept Neurol, Taoyuan, Taiwan
[6] Chang Gung Univ, Coll Med, Taoyuan, Taiwan
关键词
Alpha-synuclein; Parkinson?s disease; Fluid biomarker; Assay; CEREBROSPINAL-FLUID BIOMARKERS; CSF BIOMARKERS; DIFFERENTIAL-DIAGNOSIS; LEWY BODIES; PLASMA; DEMENTIA; PROTEINS; MARKERS; MOTOR; DJ-1;
D O I
10.1016/j.neuint.2022.105358
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Purpose: Different studies have reported varying alpha-synuclein values in the cerebrospinal fluid (CSF), serum, and plasma, making determination of the alpha-synuclein cutoff value for Parkinson's disease difficult and rendering identifying the cause of variation essential. Method: We searched PubMed from inception to June 2021 and identified 76 eligible studies. Included studies reported data on total, phosphorylated, and oligomeric alpha-synuclein in the CSF, serum, or plasma from individuals with Parkinson's disease and healthy controls. The mean or median alpha-synuclein values from the included studies were summarized and categorized through laboratory assays to visualize potential trends. Results: The enzyme-linked immunosorbent assay (ELISA) is the most common assay used to determine alphasynuclein concentrations. Less common assays include Luminex, single molecule arrays, electrochemiluminescence, and immunomagnetic reduction (IMR). IMR is a single-antibody and wash-free immunoassay designed for determining the extremely low concentration of bio-molecules. For patients with Parkinson's disease, the median or mean testing values ranged from 60.9 to 55,000 pg/mL in the CSF, 0.446 to 1,777,100 pg/ mL in plasma, and 0.0292 to 38,200,000 pg/mL in serum. The antibody selection was diverse between studies. The tendency of distribution was more centralized among studies that used the same kit. Studies adopting specific antibodies or in-house assays contribute to the extreme values. Only a few studies on phosphorylated and oligomeric alpha-synuclein were included. Conclusion: The type of assay and antibody selection in the laboratory played major roles in the alpha-synuclein variation. Studies that used the same assay and kit yielded relatively unanimous results. Furthermore, IMR may be a promising assay for plasma and serum alpha-synuclein quantification. A consensus on sample preparation and testing protocol unification is warranted in the future.
引用
收藏
页数:9
相关论文
共 101 条
  • [1] Elevated levels of cerebrospinal fluid α-synuclein oligomers in healthy asymptomatic LRRK2 mutation carriers
    Aasly, Jan O.
    Johansen, Krisztina K.
    Bronstad, Gunnar
    Waro, Bjorg J.
    Majbour, Nour K.
    Varghese, Shiji
    Alzahmi, Fatimah
    Paleologou, Katerina E.
    Amer, Dena A. M.
    Al-Hayani, Abdulmonem
    El-Agnaf, Omar M. A.
    [J]. FRONTIERS IN AGING NEUROSCIENCE, 2014, 6
  • [2] Relationship Between Cerebrospinal Fluid Biomarkers and Structural Brain Network Properties in Parkinson's Disease
    Abbasi, Nooshin
    Mohajer, Bahram
    Abbasi, Sima
    Hasanabadi, Payam
    Abdolalizadeh, Amirhussein
    Rajimehr, Reza
    [J]. MOVEMENT DISORDERS, 2018, 33 (03) : 431 - 439
  • [3] Preanalytical Stability of CSF Total and Oligomeric Alpha-Synuclein
    Abdi, Ilham Y.
    Majbour, Nour K.
    Willemse, Eline A. J.
    van de Berg, Wilma D. J.
    Mollenhauer, Brit
    Teunissen, Charlotte E.
    El-Agnaf, Omar M.
    [J]. FRONTIERS IN AGING NEUROSCIENCE, 2021, 13
  • [4] CSF α-synuclein does not differentiate between parkinsonian disorders
    Aerts, M. B.
    Esselink, R. A. J.
    Abdo, W. F.
    Bloem, B. R.
    Verbeek, M. M.
    [J]. NEUROBIOLOGY OF AGING, 2012, 33 (02) : 430.e1 - 430.e3
  • [5] Albillos SM, 2021, TREMOR OTHER HYPERK, V11
  • [6] Cerebrospinal Fluid Patterns and the Risk of Future Dementia in Early, Incident Parkinson Disease
    Backstrom, David C.
    Domellof, Magdalena Eriksson
    Linder, Jan
    Olsson, Bob
    Ohrfelt, Annika
    Trupp, Miles
    Zetterberg, Henrik
    Blennow, Kaj
    Forsgren, Lars
    [J]. JAMA NEUROLOGY, 2015, 72 (10) : 1175 - 1182
  • [7] Blood Contamination in CSF and Its Impact on Quantitative Analysis of Alpha-Synuclein
    Barkovits, Katalin
    Kruse, Niels
    Linden, Andreas
    Toenges, Lars
    Pfeiffer, Kathy
    Mollenhauer, Brit
    Marcus, Katrin
    [J]. CELLS, 2020, 9 (02)
  • [8] High discriminatory ability of peripheral and CFSF biomarkers in Lewy body diseases
    Bougea, Anastasia
    Stefanis, Leonidas
    Emmanouilidou, Evangelia
    Vekrelis, Kostas
    Kapaki, Elisabeth
    [J]. JOURNAL OF NEURAL TRANSMISSION, 2020, 127 (03) : 311 - 322
  • [9] Salivary alpha-synuclein as a biomarker for Parkinson's disease: a systematic review
    Bougea, Anastasia
    Koros, Christos
    Stefanis, Leonidas
    [J]. JOURNAL OF NEURAL TRANSMISSION, 2019, 126 (11) : 1373 - 1382
  • [10] Correlation between decreased CSF α-synuclein and Aβ1-42 in Parkinson disease
    Buddhala, Chandana
    Campbell, Meghan C.
    Perlmutter, Joel S.
    Kotzbauer, Paul T.
    [J]. NEUROBIOLOGY OF AGING, 2015, 36 (01) : 476 - 484